AU1694295A - Benzoxazinones as inhibitors of hiv reverse transcriptase - Google Patents

Benzoxazinones as inhibitors of hiv reverse transcriptase

Info

Publication number
AU1694295A
AU1694295A AU16942/95A AU1694295A AU1694295A AU 1694295 A AU1694295 A AU 1694295A AU 16942/95 A AU16942/95 A AU 16942/95A AU 1694295 A AU1694295 A AU 1694295A AU 1694295 A AU1694295 A AU 1694295A
Authority
AU
Australia
Prior art keywords
benzoxazinones
inhibitors
reverse transcriptase
hiv reverse
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU16942/95A
Inventor
Susan F. Britcher
William C. Lumma
Linda S Payne
Lekhanh O. Tran
Steven D. Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of AU1694295A publication Critical patent/AU1694295A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/18—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU16942/95A 1994-01-28 1995-01-24 Benzoxazinones as inhibitors of hiv reverse transcriptase Abandoned AU1694295A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18800594A 1994-01-28 1994-01-28
US188005 1994-01-28
PCT/US1995/001148 WO1995020389A1 (en) 1994-01-28 1995-01-24 Benzoxazinones as inhibitors of hiv reverse transcriptase

Publications (1)

Publication Number Publication Date
AU1694295A true AU1694295A (en) 1995-08-15

Family

ID=22691388

Family Applications (1)

Application Number Title Priority Date Filing Date
AU16942/95A Abandoned AU1694295A (en) 1994-01-28 1995-01-24 Benzoxazinones as inhibitors of hiv reverse transcriptase

Country Status (2)

Country Link
AU (1) AU1694295A (en)
WO (1) WO1995020389A1 (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2184075T3 (en) * 1996-03-19 2003-04-01 Searle & Co ELECTROPHILE KETONES FOR THE TREATMENT OF INFECTIONS BY HERPESVIRUS.
US6673784B1 (en) 1996-03-19 2004-01-06 G. D. Searle & Co. Electrophilic ketones for the treatment of herpesvirus infections
US6147210A (en) * 1996-07-26 2000-11-14 Dupont Pharmaceuticals Company Practical synthesis of benzoxazinones useful as HIV reverse transcriptase inhibitors
WO1998004535A1 (en) * 1996-07-26 1998-02-05 Du Pont Pharmaceuticals Company A practical synthesis of benzoxazinones useful as hiv reverse transcriptase inhibitors
US5932726A (en) * 1996-12-16 1999-08-03 Dupont Pharmaceuticals Company Asymmetric synthesis of benzoxazinones
ZA9711256B (en) 1996-12-16 1999-06-15 Du Pont Merck Pharma Asymmetric synthesis of benzoxazinones
PL197740B1 (en) * 1997-02-05 2008-04-30 Merck & Co Inc Method of crystallising and inhibitor of reverse hiv transcriptase using an antisolvent
US5965729A (en) 1997-02-05 1999-10-12 Merck & Co., Inc. Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
CA2285000A1 (en) * 1997-04-07 1998-10-15 Dupont Pharmaceuticals Company Asymmetric synthesis of benzoxazinones via new intermediates
AR011731A1 (en) * 1997-05-16 2000-08-30 Merck & Co Inc AN EFFICIENT ENANTIOSELECTIVE ADDITION REACTION PROCESS USING AN ORGANOZINC REAGENT.
US6072094A (en) * 1997-08-06 2000-06-06 Merck & Co., Inc. Efficient synthesis of cyclopropylacetylene
AU9023998A (en) * 1997-09-02 1999-03-22 Du Pont Pharmaceuticals Company 5,5-disubstituted-1,5-dihydro-4,1-benzoxazepin-2(3h)-ones useful as hiv reverse transcriptase inhibitors
HRP990030A2 (en) * 1998-02-17 1999-10-31 Michael B. Maurin Oral liquid formulations of benzoxazinones hiv reverse transcriptase inhibitors
ZA99981B (en) * 1998-02-17 2000-08-08 Du Pont Pharm Co Oral liquid formulations of benzoxazinones HIV reverse transcriptase inhibitors.
AU3199099A (en) * 1998-03-27 1999-10-18 Du Pont Pharmaceuticals Company 4,4-disubstituted-3,4-dihydro-2(1h)-quinazolinthione derivatives, their preparation and their use as hiv reverse transcriptase inhibitors
UA72207C2 (en) * 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Pharmaceutical formulations of efavirenz and disintegrants providing for increasing dissolution rate and process of manufacturing such tablets or capsules
EP1332757B1 (en) * 1998-05-27 2012-06-13 Merck Sharp & Dohme Corp. Efavirenz compressed tablet formulation
CO5070643A1 (en) * 1998-05-27 2001-08-28 Merck & Co Inc FORMULATION IN COMPRESSED TABLETS
US20010014352A1 (en) 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
HRP990182A2 (en) * 1998-06-11 2000-02-29 Du Pont Pharm Co Crystalline efavirenz
US6673372B1 (en) 1998-06-11 2004-01-06 Bristol-Myers Squibb Pharma Company Crystalline Efavirenz
US6509334B1 (en) 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6380178B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Cyclic regimens using cyclocarbamate and cyclic amide derivatives
US6399593B1 (en) 1999-05-04 2002-06-04 Wyeth Cyclic regimens using cyclic urea and cyclic amide derivatives
US6319912B1 (en) 1999-05-04 2001-11-20 American Home Products Corporation Cyclic regimens using 2,1-benzisothiazoline 2,2-dioxides
US6498154B1 (en) 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
US6444668B1 (en) 1999-05-04 2002-09-03 Wyeth Combination regimens using progesterone receptor modulators
US6306851B1 (en) 1999-05-04 2001-10-23 American Home Products Corporation Cyclocarbamate and cyclic amide derivatives
US6380235B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Benzimidazolones and analogues
US6407101B1 (en) * 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6423699B1 (en) 1999-05-04 2002-07-23 American Home Products Corporation Combination therapies using benzimidazolones
US6329416B1 (en) 1999-05-04 2001-12-11 American Home Products Corporation Combination regimens using 3,3-substituted indoline derivatives
US6358948B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
US6462032B1 (en) 1999-05-04 2002-10-08 Wyeth Cyclic regimens utilizing indoline derivatives
NZ515353A (en) * 1999-05-04 2004-03-26 Ligand Pharm Inc Cyclothiocarbamate derivatives as progesterone receptor modulators
US6417214B1 (en) 1999-05-04 2002-07-09 Wyeth 3,3-substituted indoline derivatives
US6369056B1 (en) 1999-05-04 2002-04-09 American Home Products Corporation Cyclic urea and cyclic amide derivatives
US6355648B1 (en) 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6358947B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Tetracyclic progesterone receptor modulator compounds and methods
US6339098B1 (en) 1999-05-04 2002-01-15 American Home Products Corporation 2,1-benzisothiazoline 2,2-dioxides
CA2371726A1 (en) * 1999-05-04 2000-11-09 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
GB2355988A (en) 1999-10-28 2001-05-09 Merck & Co Inc Synthesis of cyclopropylacetylene in a one-pot process using a diazo-keto-phos phonate
GB2355724A (en) 1999-10-28 2001-05-02 Merck & Co Inc Synthesis of cyclopropylacetylene from propiolic acid (2-propynoic acid)
UA73119C2 (en) * 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
ES2549084T3 (en) * 2007-10-05 2015-10-22 Msd K.K. Benzoxazinone derivatives
EP2417097A2 (en) 2009-04-09 2012-02-15 Lonza Ltd. Autocatalytic process for the synthesis of chiral propargylic alcohols
WO2010115639A1 (en) 2009-04-09 2010-10-14 Lonza Ltd Process for the synthesis of a propargylic alcohol
EP2447255A1 (en) 2010-10-14 2012-05-02 Lonza Ltd. Process for the synthesis of cyclic carbamates
EP2447247A1 (en) 2010-10-14 2012-05-02 Lonza Ltd. Process for the synthesis of chiral propargylic alcohols
EP2471783A1 (en) 2010-12-23 2012-07-04 Esteve Química, S.A. Novel polymorphic form of efavirenz
WO2012097511A1 (en) * 2011-01-19 2012-07-26 Lonza Ltd Dmp-266 by cyclisation
DE202015104551U1 (en) 2015-08-27 2015-12-03 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Reactors for the production of efavirenz and intermediates

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3526621A (en) * 1966-08-03 1970-09-01 Farmaceutical Italia Soc Substituted 3,1-benzoxazin-2-one

Also Published As

Publication number Publication date
WO1995020389A1 (en) 1995-08-03

Similar Documents

Publication Publication Date Title
AU1694295A (en) Benzoxazinones as inhibitors of hiv reverse transcriptase
AU1046895A (en) New quinazolines as inhibitors of hiv reverse transcriptase
AU641769B2 (en) Inhibitors of HIV reverse transcriptase
AU2216292A (en) Inhibitors of hiv reverse transcriptase
SG80631A1 (en) Inhibitors of hiv reverse transcriptase
AU2436792A (en) Quinazoline derivatives as inhibitors of hiv reverse transcriptase
AU8596191A (en) Hydroxylated inhibitors of hiv reverse transcriptase
PL310410A1 (en) Inhibitors of reverse hiv transcriptase
AU8693491A (en) Synergism of hiv reverse transcriptase inhibitors
AU3118200A (en) Hiv integrase inhibitors
AU1408300A (en) Hiv infection inhibitors
AU3841393A (en) New quinazolines as inhibitors of HIV reverse transcriptase
AUPM982594A0 (en) HIV protease inhibitors
AU1750497A (en) Compounds capable of inhibiting hiv-1 infection
AU6828894A (en) Hiv protease inhibitors
AU7666496A (en) Structure based design of inhibitors of hiv-1 reverse transcriptase
AU4698399A (en) 1,3-benzodiazepin-2-ones and 1,3-benzoxazepin-2-ones useful as hiv reverse transcriptase inhibitors
AU7845191A (en) Inhibitors of HIV reverse transcriptase
AU2473695A (en) Method of slowing the progression of hiv infection
AU3736197A (en) A practical synthesis of benzoxazinones useful as hiv reverse transcripta se inhibitors
AU2231199A (en) Alkenyldiarylmethane non-nucleoside hiv-1 reverse transcriptase inhibitors
AU3199099A (en) 4,4-disubstituted-3,4-dihydro-2(1h)-quinazolinthione derivatives, their preparation and their use as hiv reverse transcriptase inhibitors
AU4719799A (en) Substituted quinolin-2(1h)-ones useful as hiv reverse transcriptase inhibitors
AU2747397A (en) Hiv protease inhibitors useful for the treatment of aids
ZA935724B (en) Benzoxazinones as inhibitors of HIV reverse transcriptase